ANZCTR search results

The primary objective of Study SCY-247-103 is to evaluate the safety, tolerability, and pharmacokinetic profile of the SCY-247 intravenous formulation following single and multiple intravenous infusion administrations in healthy participants. The results from this study will inform and support dose selection for subsequent clinical studies.

The study examines the effects of an 8-week high-intensity interval training (HIIT) program, involving two 30-minute sessions per week, in two groups of people with multiple sclerosis—those with high and low levels of fatigue. The aim is to measure changes in fatigue, cognitive function, and biological processes related to metabolism and gut microbiome diversity. It is expected that both groups will show benefits from the program, but that the extent and pattern of improvement will differ depending on participants’ baseline fatigue levels.

This study investigates whether adding a gel containing a naturally occurring molecule that helps with wound healing, hyaluronic acid (HA), can improve treatment outcomes for people with an infection around dental implants that causes gum inflammation and bone loss (peri-implantitis). The hypothesis is that the additional use of the gel will improve clinical outcomes.

The Critical Illness, Inflammation, and Immunology (CI3) Biobank has been developed to improve insights into the immune mechanisms that contribute to critical illness. Our aims are to develop a world-class biospecimen repository that will support future translational research in this area. Using careful safeguards to protect patient privacy we will link a range of biological specimens to detailed demographic, diagnostic, management, and patient-reported outcome data. Working in partnership with leading researchers we hope to provide new insights into the immunobiology and inflammation in critical illnesses with a focus on identifying novel treatment strategies, improving patient care and outcomes.

This randomised controlled trial is the third phase of the ReMedi project and will evaluate a co-designed, consumer-focused digital platform to support reporting and management of medicine side-effects. The ReMedi platform enables consumers to easily report side-effects directly to the Therapeutic Goods Administration (TGA), share reports with their healthcare professionals, and keep a personal record of their experiences. The service aims to empower consumers to recognise and report medicine side-effects early and to support follow-up care by pharmacists and general practitioners. By improving consumer engagement in side-effects reporting, ReMedi may increase both the number and quality of reports submitted to the TGA, helping to strengthen medicine safety monitoring and regulatory decision-making. The trial will compare ReMedi alone with ReMedi plus SMS reminders to assess feasibility, usability, and implementation in real-world community pharmacy and general practice settings. The study will recruit 806 participants from sites in Adelaide, South Australia. The expected outcome is an easy-to-use, stakeholder-acceptable platform for medicine side-effect reporting and management that enhances consumer engagement.

When children have high levels of anxiety (fear or worry), this can prevent the student from learning or engaging in class. Many primary school teachers report not receiving enough training to help their students with anxiety effectively. We have developed a teacher training program designed to improve educators’ understanding of childhood anxiety and how to support students. Initial testing of the program showed promising results, and we now aim to test this program with more teachers nationwide using quantitative and qualitative research methodologies through surveys for primary school teachers in Australia. We hypothesise that the teacher training program will increase teachers' knowledge, confidence, and behavioural practices when identifying and supporting students with anxiety, and reduce anxiety-related stigma (attitudes towards anxiety disorders).

Sterile water injections are used by midwives to manage back pain during labour. The only side effect is the intense pain of the injections due to the lack of salt ions in sterile water. This placebo controlled double blind study aims to assess if a small concentration of salt added to the sterile water (0.2%) will reduce the pain of the injections. We hypothesize that the alternative low salt concentration solution will provide a more acceptable alternative to sterile water improving acceptability while maintaining clinical effectiveness.

This study is testing whether the eye drop CT2000 is safe and can help reduce eye pain in people with moderate to severe Dry Eye Disease. About 120 adults will take part. The first part will find a safe dose, and the second part will compare CT2000 with a placebo (inactive eye drop) and explore any reduction in eye pain. The main goal is to see if CT2000 is safe to use and if it can reduce eye pain.

Research indicates that Cognitive Behaviour Therapy (CBT) is an effective intervention for gambling disorder. However, few people (5-10%) with risky gambling access help services. Even then, drop-out rates remain high. We will compare AI chatbot powered inter-session homework activities in conjunction with Cognitive Behavioural Therapy (CBT) and standard care, versus CBT and standard care alone. We will assess gambling behaviour, mental health and quality of life outcomes for problem gamblers. The intended outcome of this trial is to generate preliminary evidence that will support clinically effective, safe implementation of Gabi whilst demonstrating improved gambling and quality of life outcomes.

This study will test whether using artificial intelligence (AI) to analyse heart CT scans can improve how doctors assess and treat coronary artery disease compared with usual care. The AI software automatically measures the amount and type of plaque in the heart arteries, providing more detailed information than standard visual reading alone. Participants will be randomly assigned to either AI-guided care or usual care, and all will have CT scans and blood tests at the start and again after 24 months. The main hypothesis is that AI-guided care will lead to a reduction in harmful non-calcified plaque in the coronary arteries over 24 months. The study will also assess whether AI-guided care increases doctors’ confidence in diagnosis and reduces the need for further heart tests and procedures.